Clinical Trial Update: An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa [Phase 3]

View source ↗

Summary

Phase 3 trial extension evaluating long-term efficacy, safety, and immunogenicity of GlaxoSmithKline's malaria vaccine in infants and children in Africa; trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Malaria vaccine (GSK candidate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 3 | Status: COMPLETED | Results posted: 2019-08-15